GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The brokerage presently has a $119.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.93% from the company’s current price.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

A number of other equities analysts have also recently commented on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, May 9th. Maxim Group reissued a “buy” rating and issued a $135.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Thursday, May 25th. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. ValuEngine raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, TheStreet cut shares of GW Pharmaceuticals PLC- from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- currently has an average rating of “Buy” and a consensus price target of $156.05.

Shares of GW Pharmaceuticals PLC- (GWPH) traded up 0.17% during trading on Monday, reaching $106.33. 209,752 shares of the company traded hands. GW Pharmaceuticals PLC- has a 12-month low of $79.62 and a 12-month high of $137.88. The firm’s 50-day moving average is $101.55 and its 200-day moving average is $115.09. The stock’s market capitalization is $2.69 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC- had a negative return on equity of 37.28% and a negative net margin of 2,112.29%. The company had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.07 million. During the same period in the prior year, the firm earned ($0.06) EPS. GW Pharmaceuticals PLC-‘s quarterly revenue was down 23.0% on a year-over-year basis. On average, equities analysts predict that GW Pharmaceuticals PLC- will post ($5.34) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Upgrades GW Pharmaceuticals PLC- (GWPH) to “Buy”” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/07/17/zacks-investment-research-upgrades-gw-pharmaceuticals-plc-gwph-to-buy.html.

Several large investors have recently made changes to their positions in GWPH. Eqis Capital Management Inc. boosted its stake in shares of GW Pharmaceuticals PLC- by 23.3% in the second quarter. Eqis Capital Management Inc. now owns 2,899 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 547 shares during the period. Creative Planning boosted its stake in shares of GW Pharmaceuticals PLC- by 1.4% in the second quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 35 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of GW Pharmaceuticals PLC- during the second quarter worth about $481,000. Point72 Asset Management L.P. boosted its stake in shares of GW Pharmaceuticals PLC- by 43.9% in the first quarter. Point72 Asset Management L.P. now owns 42,600 shares of the biopharmaceutical company’s stock worth $5,152,000 after buying an additional 13,000 shares during the period. Finally, FNY Partners Fund LP boosted its stake in shares of GW Pharmaceuticals PLC- by 116.7% in the first quarter. FNY Partners Fund LP now owns 3,900 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 2,100 shares during the period. 75.63% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.